Balazs Awarded NIDA Avenir Award

Date: June 29, 2015 By:

The National Institute on Drug Abuse (NIDA) recently announced the first recipients of its two newly developed Avenir Award programs for HIV/AIDS and genetics research. The Avenir (meaning “future” in French) Awards support early stage investigators who propose highly innovative studies. The six scientists will each receive up to $300,000 per year for five years to support their research.

Ragon Institute faculty member Alejandro B. Balazs, Ph.D., was one of six recipients of this award for his project entitled “Engineering Humoral Immunity to Functionally Cure HIV Infection.”

“Thanks to this new award, my laboratory will be able to focus on understanding the potential of antibodies to control active HIV infections,” said Dr. Balazs. “Through the Avenir New Innovator Award we will seek to develop engineered immunity that is capable of permanently suppressing virus replication from a single injection. This approach could one day result in new treatments for vulnerable patients who have trouble controlling their virus with existing drugs.”
Read more about the NIDA Avenir New Innovator Award.



More News

Confirmed High Levels of SARS-CoV-2 Virus in Children


Global Infectious Diseases

When Good T cells Go Bad

In a paper recently published in Immunity, Ragon researchers found that, in these cases, control is lost after a type of immune cell, known as a cytotoxic T cell, loses the ability to proliferate and kill HIV-infected cells.


Clinical Research

HIV Vaccine Trial “Imbokodo” Will Not Progress to Next Steps